Because high PRMT3 expression inhibited anti-tumor immunity and efficacy of ICB by methylating HSP60, our findings suggested that PRMT3 might be an important regulator of secondary immunotherapy resistance in HCC. This evidence concerns the gene HSPD1 and neoplasm.